Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906089 | 0.82 | KMT2A (0.38) | KMT2ATSHRLMNACHRM2CHRM4 | |
| SCHEMBL31461600 | 0.80 | KMT2A (0.33) | KMT2ATSHRLMNACHRM2CHRM4 | |
| SCHEMBL18359697 | 0.77 | TSHR (0.38) | TP53TSHR | |
| SCHEMBL846987 | 0.77 | TSHR (0.38) | TP53TSHR | |
| SCHEMBL13725057 | 0.77 | TSHR (0.38) | TP53TSHR | |
| SCHEMBL23673200 | 0.77 | TP53 (0.50) | TP53KMT2ATSHRCYP2C9 | |
| SCHEMBL44463 | 0.77 | TP53 (0.50) | TP53KMT2ATSHRCYP2C9 | |
| SCHEMBL8557040 | 0.77 | TP53 (0.50) | TP53KMT2ATSHRCYP2C9 | |
| SCHEMBL18651139 | 0.77 | TP53 (0.50) | TP53KMT2ATSHRCYP2C9 | |
| SCHEMBL21768461 | 0.77 | TP53 (0.50) | TP53KMT2ATSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877419-B1 | CRYSTALLINE SQUALAMINE DILACTATE | ENTERIN INC (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-2527355-B1 | Polymorphic and amorphous salt forms of squalamine dilactate | ENTERIN INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-8716270-B2 | Polymorphic and amorphous salt forms of squalamine dilactate | OHR PHARMACEUTICAL INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120022035-A1 | Polymorphic and Amorphous Salt Forms of Squalamine Dilactate | ENTERIN, INC. | 2012-01-26 | — | — | US | disclosed |
| US-7981876-B2 | Polymorphic and amorphous salt forms of squalamine dilactate | Ohr Pharmaceuticals, Inc. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7956237-B2 | Using transgenic animal models as tools in identifying and treating cell proliferative, cardiovascular, vision, muscular, nervous system, bone and metabolic disorders | GENENTECH, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110061114-A1 | NOVEL PRO258 GENE DISRUPTIONS, AND METHODS RELATING THERETO | EDWARDS JOEL A | 2011-03-10 | — | — | US | disclosed |
| US-20080160034-A1 | Using transgenic animal models as tools in identifying and treating cell proliferative, cardiovascular, vision, muscular, nervous system, bone and metabolic disorders | GENENTECH, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1877419-A2 | POLYMORPHIC AND AMORPHOUS SALT FORMS OF SQUALAMINE DILACTATE | Genaera Corporation (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1781824-A2 | NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO | GENENTECH, INC. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070010504-A1 | Polymorphic and amorphous salt forms of squalamine dilactate | ENTERIN, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2006116309-A2 | POLYMORPHIC AND AMORPHOUS SALT FORMS OF SQUALAMINE DILACTATE | GENAERA CORPORATION (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006026222-A2 | NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO | GENENTECH, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-0286252-A2 | Anti-cancer composition & method featuring cyanine dyes | DANA FARBER CANCER INSTITUTE (US) | 1988-10-12 | — | — | EP | disclosed |